Risk factors can guide screening decisions for younger women

Updated, Subgroup Analyses of BOLERO-2 Confirm Efficacy of Everolimus plus Exemestane in Postmenopau
Updated, Subgroup Analyses of BOLERO-2 Confirm Efficacy of Everolimus plus Exemestane in Postmenopau

Younger women at increased risk for breast cancer may benefit from mammography screening performed once every 2 years beginning at age 40 years, according to two studies funded by the National Cancer Institute. 


In one project, data synthesized from 66 published studies showed that having extremely dense breasts on mammography or first-degree relatives with breast cancer doubled the risk of breast cancer for a woman aged 40 to 49 years. Risk was even higher among women with two or more first-degree relatives with breast cancer or a first-degree relative with a diagnosis before age 40 years.


Having a prior benign breast biopsy result, second-degree relatives with breast-cancer, or heterogeneously dense breasts was associated with a 1.5-fold to 2-fold increased risk. Women who currently used oral contraceptives, who had never given birth, or who were at least 30 years old at first birth had an increased risk of 1.0-fold to 1.5-fold. 


Although most women who develop breast cancer have no known risk factors, information about risk may be particularly useful when making decisions about screening women in their 40s, noted the investigators (Annals of Internal Medicine. 2012;156[9]:
635-648). 


The second study, published along with the first (pp. 609-617) and conducted by several authors of the first study, revealed that for women aged 40 to 49 years with a 2.0-fold increased risk for breast cancer, the harm-benefit ratio of biennial screening with film mammography was similar to that of biennial screening of average-risk women aged 50 to 74 years. This suggests that for that group of younger women, biennial screening at age 40 years has more benefits than harms. ONA

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in In the News

Fear of lymphedema after sentinel lymph node biopsy greater than risk

Fear of lymphedema after sentinel lymph node biopsy ...

Despite the low risk of lymphedema after sentinel lymph node biopsy, most women worry about this complication and practice risk-reducing behaviors to avoid it.

25-year survival after prostate radiation matches prostatectomy

25-year survival after prostate radiation matches prostatectomy

Late recurrence of prostate cancer is rare if PSA is less than 0.2 ng/mL, the surgical PSA definition of cancer control, 15 years after treatment with radiation therapy.

Diet can thwart prostate 
cancer progression

Diet can thwart prostate 
cancer progression

Men with early-stage prostate cancer may be able to inhibit tumor growth and progression by following a high-fiber diet.